Celyad Oncology S.A.
CLYYF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $186 | $102 | $0 | $0 |
| % Growth | 82.4% | – | – | – |
| Cost of Goods Sold | -$733 | $69 | $1,440 | $1,520 |
| Gross Profit | $919 | $33 | -$1,440 | -$1,520 |
| % Margin | 494.1% | 32.4% | – | – |
| R&D Expenses | $2,886 | $4,668 | $17,697 | $19,496 |
| G&A Expenses | $3,088 | $5,707 | $10,337 | $9,665 |
| SG&A Expenses | $4,292 | $6,250 | $10,337 | $9,665 |
| Sales & Mktg Exp. | $78 | $215 | $0 | $0 |
| Other Operating Expenses | $0 | -$2,428 | $0 | $328 |
| Operating Expenses | $7,178 | $8,490 | $28,034 | $29,489 |
| Operating Income | -$6,259 | -$10,597 | -$29,474 | -$26,391 |
| % Margin | -3,365.1% | -10,389.2% | – | – |
| Other Income/Exp. Net | $299 | $1,958 | -$11,858 | -$111 |
| Pre-Tax Income | -$5,960 | -$8,639 | -$41,332 | -$26,502 |
| Tax Expense | -$136 | -$191 | $65 | $10 |
| Net Income | -$5,824 | -$8,448 | -$40,935 | -$26,512 |
| % Margin | -3,131.2% | -8,282.4% | – | – |
| EPS | -0.14 | -0.33 | -1.81 | -1.7 |
| % Growth | 57.6% | 81.8% | -6.5% | – |
| EPS Diluted | -0.14 | -0.33 | -1.81 | -1.7 |
| Weighted Avg Shares Out | 41,429 | 25,722 | 22,594 | 15,604 |
| Weighted Avg Shares Out Dil | 41,429 | 25,722 | 22,594 | 15,604 |
| Supplemental Information | – | – | – | – |
| Interest Income | $153 | $30 | $12 | $27 |
| Interest Expense | $119 | $84 | $197 | $255 |
| Depreciation & Amortization | $450 | $794 | $1,440 | $1,520 |
| EBITDA | -$5,391 | -$7,763 | -$39,695 | -$25,414 |
| % Margin | -2,898.4% | -7,610.8% | – | – |